tetano
Editor, Senior Moderator
Obstet Gynecol
. 2022 Jan 13.
doi: 10.1097/AOG.0000000000004700. Online ahead of print.
Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Bright P Thilagar[SUP] 1 [/SUP], Aditya K Ghosh, Jerome Nguyen, Regan N Theiler, Myra J Wick, Ryan T Hurt, Raymund R Razonable, Ravindra Ganesh
Affiliations
No abstract available
Conflict of interest statement
Financial Disclosure Ryan T. Hurt is a consultant for Nestle Nutrition. Raymund R. Razonable is principal investigator of clinical trials on COVID-19 treatment funded by Gilead (remdesivir), Regeneron (sarilumab, casirivimab-imdevimab), Roche (tocilizumab), and research on Monoclonal Antibody Therapy funded by the Mayo Clinic. They have been on the data safety monitoring board for a Novartis clinical trial. They disclosed that bamlanivimab, bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab are all investigational products authorized for emergency use EUA by the U.S. FDA. The other authors did not report any potential conflicts of interest.
. 2022 Jan 13.
doi: 10.1097/AOG.0000000000004700. Online ahead of print.
Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Bright P Thilagar[SUP] 1 [/SUP], Aditya K Ghosh, Jerome Nguyen, Regan N Theiler, Myra J Wick, Ryan T Hurt, Raymund R Razonable, Ravindra Ganesh
Affiliations
- PMID: 35026789
- DOI: 10.1097/AOG.0000000000004700
No abstract available
Conflict of interest statement
Financial Disclosure Ryan T. Hurt is a consultant for Nestle Nutrition. Raymund R. Razonable is principal investigator of clinical trials on COVID-19 treatment funded by Gilead (remdesivir), Regeneron (sarilumab, casirivimab-imdevimab), Roche (tocilizumab), and research on Monoclonal Antibody Therapy funded by the Mayo Clinic. They have been on the data safety monitoring board for a Novartis clinical trial. They disclosed that bamlanivimab, bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab are all investigational products authorized for emergency use EUA by the U.S. FDA. The other authors did not report any potential conflicts of interest.